CME

Faculty: A.J. Gelderblom, MD, PhD This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitor...

Faculty: Michiel van de Sande, MD, PhD This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhi...

Faculty: A.J. Gelderblom, MD, PhD This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitor...

Host: Pushpa Narayanaswami, MD, FAAN In this expert commentary, Dr. Narayanaswami highlights key messages from the Prova Education satellite symposium held at the 2025 AANEM Meeting in San Francisco. The discussion centers on the clinical application of FcRn antagonists in gMG, reviewing the rationale for FcRn blockade, approved FcRN antagonists, and pivotal clinical trial data. Differences in the...

Faculty: Michael Collins This CME activity focuses on enhancing clinician recognition and management of autosomal dominant hypocalcemia type 1 (ADH1). Learners will explore the pathophysiology and clinical manifestations of ADH1, understand barriers to timely diagnosis, gain practical strategies for implementing and interpreting genetic testing, and evaluate emerging therapies—such as calcilytics—...

Faculty: Tina Q. Tan, MD Faculty: Yvonne Maldonado, MD This three-part educational activity reviews the burden of respiratory syncytial virus (RSV) and evidence-based strategies to prevent disease in infants and young children. Chapter 1 examines the epidemiology of RSV and outlines current prophylactic options, including maternal vaccination and the monoclonal antibodies nirsevimab (approved 2023...

Faculty: Luca Busetto, MD Faculty: Kirsi H Pietiläinen, MD, PhD Expert faculty Drs. Luca Busetto and Kirsi H. Pietiläinen discuss the importance of early intervention in obesity management to prevent progression and obesity related complications. They examine the evolving therapeutic landscape, including GLP-1 and GIP-based medications like semaglutide and tirzepatide. The conversation highlights...

Host: Scott Kopetz, MD, PhD Host: Cathy Eng, MD, FACP This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

Host: Marc A. Riedl, MD, MS On-demand webcast with expert faculty presentation on addressing the unmet needs and optimizing treatment for hereditary angioedema (HAE), including long-term prophylaxis therapy, for patients with HAE.

Faculty: Jose Rubio, MD Faculty: Jonathan M. Meyer In this Chairperson’s Perspective, Dr. Jose Rubio and Dr. Jonathan Meyer explore the evolving landscape of schizophrenia treatment through muscarinic receptor modulation. They compare the mechanisms of action, efficacy, and side effect profiles of muscarinic antipsychotics, such as xanomeline-trospium, with traditional dopamine D2 antagonists. The...

Faculty: Jörg Latus, MD Faculty: Jürgen Floege, MD Dr. Jürgen Floege, co-chair of the KDIGO Work Group, and Dr. Jörg Latus review the updated KDIGO 2025 guidelines for managing immunoglobulin A nephropathy (IgAN) and IgA vasculitis (IgAV), which emphasize diagnostic criteria, proteinuria-based treatment thresholds, and revised therapeutic goals. The discussion focuses on the new KDIGO proteinuria...

Faculty: Scott Solomon, MD Enhance your ability to apply shared decision-making in patients with HF and LVEF ≥40%. Through real-world clinical vignettes, Dr. Scott Solomon illustrates how to uncover patient goals, clearly communicate risks and benefits, and build collaborative treatment plans. The session emphasizes early use of SGLT2 inhibitors and finerenone to reduce hospitalizations, improve q...

Faculty: Joyce F. Liu, MD, MPH Faculty: Kathleen Moore, MD, MS Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to de...

Faculty: Kathleen Moore, MD, MS Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents d...

Faculty: Joyce F. Liu, MD, MPH Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents di...

Faculty: Kathleen Moore, MD, MS Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents d...

Faculty: Joyce F. Liu, MD, MPH Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents di...

Faculty: Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC Faculty: Javed Butler, MD Faculty: Stephen J. Greene, MD, FACC, FHFSA For patients with heart failure with reduced ejection fraction (HFrEF), optimizing therapy is an important part of treatment and care. But not all patients may be reaching their treatment goals and can continue to face substantial residual risk despite the use of...

Faculty: Naim Alkhouri, MD, FAASLD, DABOM Metabolic dysfunction-associated steatohepatitis (MASH) with compensated cirrhosis is associated with poor prognosis due to a high risk of hepatic decompensation, hepatocellular carcinoma, cardiovascular events, and death. Using noninvasive diagnostic tools like FIB-4, VCTE, and Agile 4, clinicians can accurately identify cirrhosis and clinically significa...

Guest: Joshua Richter, MD This activity will cultivate familiarity with the emerging CELMoD treatment class poised to transform the management of newly-diagnosed and R/R MM. With a higher affinity for cereblon than their predecessors, CELMoDs represent a new, distinct generation of immunomodulatory drugs with the potential to bridge longstanding treatment gaps for patients exhibiting inadequate re...

Host: Stephen Chrzanowski, MD, PhD Guest: Aravindhan Veerapandiyan, MD Corticosteroids remain a cornerstone in Duchenne muscular dystrophy (DMD) management, but evolving therapies demand a more nuanced approach. This case-based activity explores how to proactively monitor and manage corticosteroid-associated side effects through interdisciplinary care coordination. Strengthen your care strategy as...

Faculty: Michael E. Thase, MD Faculty: Andrew Krystal, MD Approximately 75% to 90% of patients with depression experience insomnia. This means that a very significant portion of individuals struggling with depression also have difficulty sleeping. Join Drs. Michael Thase and Andrew Krystal for this expert discussion to learn about the most recent data presented at the Psych Congress 2025 in San Di...

Faculty: prof. Hiddo Heerspink Faculty: Peter Rossing, MD, DMSc Faculty: Paola Fioretto, MD Chronic kidney disease (CKD) is a common complication in type 2 diabetes that is closely linked to cardiovascular risk and often diagnosed late. Early detection with UACR and eGFR, plus treatment with therapies such as SGLT2 inhibitors, finerenone, and GLP-1 receptor agonists, has transformed treatment and...

Host: Lisa Phipps, PharmD, PhD Guest: Michael Sprintz, DO, DFASAM Guest: Amanda Zimmerman, PA-C This Opioid Analgesic REMS webcast provides an FDA Blueprint-aligned learning experience to support safe, compassionate pain management through thorough assessment and individualized treatment planning. Also covered is counseling on safe opioid use, storage, and disposal; monitoring for misuse; and scre...

Guest: Jaime Almandoz, MD, MBA, MRCPI, FTOS, DABOM Guest: Radhika S. Breaden, MD, MPH, DABMS, DABOM Guest: H-C Carol Huang, BHB, MBChB, FRACP Guest: Babak Mokhlesi, MD, MSc Guest: Amanda J. Piper, PhD Guest: Rafael Sepulveda, MD, DABMS, DABOM Guest: Audrey Wells, MD On-demand webcast of expert faculty presentation on the connection between obstructive sleep apnea (OSA) and obesity, including strat...